$35.450
+1.875 (+5.29%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de CAI por análisis de gráficos similares
Alphio's CAI stock price prediction model matches the current Caris Life Sciences, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $35.45 (+0.01%). The 1-week path is $35.52 (+0.20%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Caris Life Sciences, Inc.?
Caris Life Sciences Inc is a good buy right now due to its current price of $32, which is supported by a strong gross margin of 68.10% in Q2 2026 and a forward P/E ratio of 43.29. The company has shown impressive revenue growth, with a 45.4% year-over-year increase in Q2 2026 revenue to $263.7 million, indicating strong market demand. However, the main risk is the high P/E ratio of 85.68, which suggests that the stock may be overvalued if growth expectations are not met.
CAI cerró en $35.45 el Wednesday, tras subir +5.29%
Caris Life Sciences, Inc. (CAI) last closed at $35.4500008, gaining +5.29%. These facts feed the 1-day and 1-week CAI price prediction above.
Factores de la previsión
Los factores de la previsión de Caris Life Sciences, Inc. (CAI) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bullish
SMA 200
Bullish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de CAI, ordenadas por similitud.
Análisis de estacionalidad de CAI
Historically the probability of a positive October return for CAI is 100.00%. October offers the highest probability of a positive month at 100.00%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.